On this page
GATM
glycine amidinotransferase
The GATM gene encodes an enzyme crucial for the initial step in creatine biosynthesis, a compound vital for cellular energy storage and utilisation. GATM provides instructions for the enzyme arginine:glycine amidinotransferase.
GATM is located on the long (q) arm of chromosome 15, at band 15q21.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 15 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The GATM gene, also known as glycine amidinotransferase, plays a fundamental role in human metabolism by coding for an enzyme called arginine:glycine amidinotransferase. This enzyme is specifically involved in the biosynthesis pathway of creatine, a molecule critical for energy supply in cells, particularly in tissues with high energy demands like muscles and the brain. Proper functioning of the GATM enzyme ensures the efficient production of creatine, which is then converted into phosphocreatine for rapid energy buffering and transfer.
What the gene does
The GATM gene provides the blueprint for the enzyme arginine:glycine amidinotransferase, often referred to as AGAT. This enzyme catalyses the first of two key steps in the body's endogenous creatine synthesis pathway. Specifically, AGAT facilitates the transfer of a guanidino group from arginine, an amino acid, to glycine, another amino acid. This reaction yields guanidinoacetic acid (GAA). Subsequently, GAA is converted to creatine in a separate enzymatic step. Creatine is essential for the storage and efficient utilisation of energy within cells, supporting vital physiological processes. Deficiencies in GATM activity can disrupt this pathway, leading to insufficient creatine levels.
Video: Genetics 101
Chromosome location
The GATM gene is situated on chromosome 15 at band 15q21.1. This precise location specifies where the gene can be found within the human genome. The protein it encodes is composed of 423 amino acids, contributing to its enzymatic function in creatine synthesis.
Protein structure
Domain architecture has not been experimentally characterised in detail for this protein.
Key variants
Genetic variations within the GATM gene can alter the function of the arginine:glycine amidinotransferase enzyme. These changes can range from small alterations in the DNA sequence to larger structural rearrangements. Such variants may lead to a reduced or absent enzyme function, thereby impacting the body's ability to produce creatine effectively. The specific impact of a variant often depends on its location and the nature of the genetic change.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1111dup | p.Met371fs | Pathogenic | ★★★☆ | Arginine:glycine amidinotransferase deficiency |
c.446G>A | p.Trp149Ter | Pathogenic | ★★★☆ | Arginine:glycine amidinotransferase deficiency |
c.484+1G>T | - | Pathogenic | ★★★☆ | Arginine:glycine amidinotransferase deficiency |
c.505C>T | p.Arg169Ter | Pathogenic | ★★★☆ | Arginine:glycine amidinotransferase deficiency |
c.629G>A | p.Trp210Ter | Pathogenic | ★★★☆ | Arginine:glycine amidinotransferase deficiency |
c.580C>T | p.Arg194Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Arginine:glycine amidinotransferase deficiency |
g.(?_45661504)_(45670651_?)del | - | Pathogenic | ★☆☆☆ | Arginine:glycine amidinotransferase deficiency |
c.141dup | p.Asn48fs | Pathogenic | ★☆☆☆ | Arginine:glycine amidinotransferase deficiency |
c.92G>A | p.Trp31Ter | Pathogenic | ★☆☆☆ | Arginine:glycine amidinotransferase deficiency |
c.964C>T | p.Arg322Ter | Pathogenic | ★☆☆☆ | Arginine:glycine amidinotransferase deficiency |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Variants in the GATM gene are associated with inherited metabolic disorders, notably those affecting creatine metabolism. One such condition is Cerebral creatine deficiency (AGAT), which can arise from insufficient activity of the GATM enzyme. This deficiency leads to a lack of creatine in the brain and other tissues, resulting in neurological symptoms.
UK clinical status
The GATM gene is recognised by NHS England's National Genomic Test Directory. It is included in several Green R-panels, indicating its relevance for diagnosing conditions such as Intellectual disability, Likely inborn error of metabolism (R98), Renal tubulopathies (R198), Tubulointerstitial kidney disease (R202), and Undiagnosed metabolic disorders. This widespread inclusion underscores the clinical significance of GATM in the UK healthcare system.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What does the GATM gene do?
The GATM gene provides instructions for making the arginine:glycine amidinotransferase enzyme, which is responsible for the first step in the body's natural production of creatine. Creatine is vital for storing and using energy in cells, especially in the brain and muscles.
What conditions are associated with GATM gene variants?
Variants in the GATM gene are primarily associated with conditions like Cerebral creatine deficiency (AGAT), which can lead to neurological issues due to insufficient creatine levels in the brain.
Is GATM testing available in the UK?
Yes, the GATM gene is included in several NHS England Genomic Test Directory panels, such as those for Intellectual disability and specific metabolic disorders, indicating its importance for diagnostic testing in the UK.
References
- Braissant O, Henry H, Béard E. Creatine deficiency syndromes and the importance of creatine synthesis in the brain. Amino acids. 2011. PMID: 21390529
- Nasrallah F, Feki M, Kaabachi N. Creatine and creatine deficiency syndromes: biochemical and clinical aspects. Pediatric neurology. 2010. PMID: 20159424
- Béard E, Braissant O. Synthesis and transport of creatine in the CNS: importance for cerebral functions. Journal of neurochemistry. 2010. PMID: 20796169
- Morris SM Jr. Enzymes of arginine metabolism. The Journal of nutrition. 2004. PMID: 15465778
- Sykut-Cegielska J, Gradowska W, Mercimek-Mahmutoglu S. Biochemical and clinical characteristics of creatine deficiency syndromes. Acta biochimica Polonica. 2004. PMID: 15625559
- Schulze A. Creatine deficiency syndromes. Molecular and cellular biochemistry. 2003. PMID: 12701824
- Item CB, Stöckler-Ipsiroglu S, Stromberger C. Arginine:glycine amidinotransferase deficiency: the third inborn error of creatine metabolism in humans. American journal of human genetics. 2001. PMID: 11555793